item management s discussion and analysis of financial condition and results of operations this information should be read in conjunction with the related consolidated financial statements and notes thereto contained elsewhere in this annual report on form k 
management s discussion and analysis general the company develops  manufactures  and sells cell and molecular biology products and cell culture products under the gibcobrl brand name 
cell and molecular biology products are used by scientists to identify  isolate  and manipulate the metabolic processes and genetic material of living organisms 
cell culture products include cell and tissue culture media  reagents  fetal bovine serum fbs  a major product of the company  and other animal sera 
these products are used by scientists to grow cells under laboratory conditions and are also used for the commercial manufacture of pharmaceuticals and other life sciences products 
results of operations revenues the major product line components of net sales for  and compare as follows amounts in thousands cell and molecular biology    cell culture    net sales    net sales for were million  an increase of million  or  over sales of products other than fbs increased million  or  over sales levels 
fbs sales were million lower in when compared with lower unit sales of fbs lowered net sales by million while higher unit selling prices increased net sales by million when compared with net sales in changes in currency exchange rates increased net sales by million when compared with net sales for were million  an increase of million  or  over sales of products other than fbs increased million  or  over sales levels 
fbs sales were million higher in than in higher unit sales of fbs increased net sales by million while lower unit selling prices reduced net sales by million when compared with currency exchange rate changes increased net sales by million when compared with fbs represented of net sales in and in and royalty income was million  million and million in  and  respectively 
royalty income represents licensing fees paid to the company for technologies developed from research efforts undertaken for the company s discontinued molecular diagnostics product line 
cost of sales gross margin gross margins were of net sales in compared with in gross margins improved in as the company consolidated the gross margins of its japanese subsidiary and because the company reported higher gross margins in markets it served directly in where these markets were served by distributors for a substantial portion of gross margins were of net sales in compared with in gross margins declined in the period principally due to lower fbs gross margins and higher royalty expense in the period 
fbs gross margins were lower because of a decline in unit selling prices and an increase in unit costs 
marketing and administrative expenses marketing and administrative expenses were of net sales in  of net sales in and of net sales in marketing and administrative expenses  expressed as a percentage of sales  increased in compared with largely because the company consolidated the results of its japanese subsidiary beginning in september of and because included a full year of expenses for new sales offices opened in research and development r d expenses research and development expenses were million in  million in and million in r d expenses in  and were primarily directed toward developing new products and business solutions for the company s customers in the life sciences research and industrial bioprocessing areas and toward improving production processes 
research and development expenses represented  and of net sales in  and  respectively 
restructuring in the fourth quarter of  more closely the company restructured its european operations to align expenses more closely with expected sales levels 
also in the fourth quarter of  the company completed the restructuring of its north american fbs collection operations with the disposition of an fbs collection subsidiary 
the restructuring charge of million in the fourth quarter of includes severance costs for ten employees who left the company as a result of the european restructuring  costs related to closing a distribution center in europe and costs related to the fbs restructuring 
operating income operating income for was million  an increase of million  or  compared with the percentage increase in operating income was greater than the percentage increase in net sales when comparing with largely because gross margins increased at a faster rate than marketing and administrative expenses 
changes in currency exchange rates used to translate non us earnings to non us dollars increased operating income in by million when compared with operating income for was million  an increase of million  or  compared with higher net sales in compared with were the primary reason for the increase in operating income 
the percentage increase in operating income was less than the percentage increase in net sales as gross margins were lower in compared with changes in currency exchange rates used to translate non us earnings to non us dollars increased operating income in by million when compared with other income and expenses investment income was million in  million in and million in investment income in  and included million  million and million  respectively  related to an interest bearing note received upon the disposition of the company s molecular diagnostics product line in late the increase in investment income was largely attributable to higher investment balances 
other income includes equity income from the company s japanese joint venture of million in  million in and million in income taxes income taxes were of pre tax income in  compared with in and minority interests income attributed to minority interest investors was million in and million in the increase is principally for minority interests in the net income of the company s japanese subsidiary 
net income net income for was million  an increase of over s net income of million 
earnings per share were in  representing a increase over the per share earnings reported in net income for was million  an increase of over net income in of million 
earnings per share were in  up compared with earnings per share of in looking ahead the company expects to concentrate on its core cell and molecular biology and cell culture product lines in  including its recently launched custom primers business 
future trends in the company s markets may be affected by government funding for life sciences research  the number of new products developed and introduced by the company s customers  and changes in technology and scientific discoveries 
the political debate in the united states and other countries with respect to reducing government budget deficits may ultimately lead to lower increases in  or levels of  government funding for research 
prior to the final outcome of these debates  research funding may periodically be delayed or reduced  especially in the us  as government budget appropriation measures are delayed during budget negotiations 
changes in currency exchange rates  the supply and price of fbs  the global economic situation and the availability of well trained employees throughout the world are factors that could have a significant effect on the company in significant strengthening of the us dollar against us currencies  especially european and japanese currencies  could have a negative impact on the company s results 
volatility in the fbs market will continue to have a significant impact on the company s results 
the market volatility of fbs and the increasing demand for alternative media provide strong incentive to develop products and technologies which are not dependent on animal sera raw materials 
the company will actively continue to seek out highly motivated and well educated individuals to become employees of the company 
heightened worldwide safety and environmental concerns are likely to lead to increased regulation in these areas 
the company is committed to promoting the safety and health of its employees and the environment and will remain pro active in complying with federal  state and local regulations 
liquidity and capital resources cash flows the company generated million in cash from operations during net income after adjustments for depreciation and amortization was the principal source of cash from operations in working capital changes in  net of business acquisitions  related principally to sales increases 
the acquisition of a controlling interest in the company s japanese joint venture  which resulted in the consolidation of that entity s financial results  increased working capital by million at the date of acquisition 
the company paid million in cash for property  plant and equipment in capital spending in was for new and replacement machinery and equipment and management information systems related to the company s ongoing business operations and for facilities expansion and modernization programs  including the company s new corporate r d center in maryland 
the company used million in for the acquisition of new businesses and to acquire a controlling interest in its japanese joint venture 
the company s balance sheet included million of debt at the end of this debt was included in the financial statements of the company s japanese subsidiary and appears as debt of the company as a result of the acquisition of a controlling interest in the subsidiary in the amount outstanding is owed to the minority shareholder and to local japanese banks 
apart from the debt consolidated with its japanese subsidiary  the company did not incur any other debt during  and there was no other debt outstanding at december  the company currently has unused lines of credit with two commercial banks totaling million and a short term revolving credit facility with the dexter corporation  an affiliate of the company  in the amount of million 
capital expenditures in are expected to range from million 
the company expects to spend approximately million in for its new corporate r d center in maryland and another million for other facilities upgrades and improvements elsewhere around the world 
the balance of expected capital spending is anticipated to be for new and replacement machinery  equipment and management information systems 
in january  the company purchased approximately of the outstanding common stock of custom primers  inc  a california based producer of oligonecleotides  for million in cash  increasing the company s ownership to 
the purchase agreement provides for an additional million in earn out contingencies based on sales of oligonucleotides over the next five years 
the company believes it will be able to generate sufficient cash from its operations and its existing credit lines to meet its anticipated working capital and capital expenditure requirements in the board of directors intends to consider the declaration and payment of quarterly dividends in the future based on the operating performance of the company 
the company is actively evaluating licensing possibilities  as well as acquisition candidates which complement the company s core cell and molecular biology and cell culture product lines 
the company may fund these transactions using cash from operations  debt  equity  or other sources 

